Last $1.22 USD
Change Today +0.03 / 2.52%
Volume 115.3K
ECTE On Other Exchanges
Symbol
Exchange
NASDAQ CM
Stuttgart
As of 8:10 PM 12/18/14 All times are local (Market data is delayed by at least 15 minutes).

echo therapeutics inc (ECTE) Snapshot

Open
$1.20
Previous Close
$1.19
Day High
$1.25
Day Low
$1.15
52 Week High
01/8/14 - $4.13
52 Week Low
09/24/14 - $0.39
Market Cap
15.4M
Average Volume 10 Days
128.3K
EPS TTM
$-1.36
Shares Outstanding
12.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ECHO THERAPEUTICS INC (ECTE)

Related News

No related news articles were found.

echo therapeutics inc (ECTE) Related Businessweek News

No Related Businessweek News Found

echo therapeutics inc (ECTE) Details

Echo Therapeutics, Inc. is engaged in the development of transdermal skin permeation and diagnostic medical devices. It is developing Symphony CGM system (Symphony), a needle-free wireless continuous glucose monitoring system for use in hospital critical care units; and Symphony SkinPrep system, a component of its Symphony for enhanced skin permeation that enables extraction of analytes, such as glucose. The company is also engaged in the development Durhalieve, an AzoneTS formulation of triamcinolone acetonide that has completed Phase III clinical trials for the treatment of corticosteroid-responsive dermatoses. It has a licensing agreement with Ferndale Pharma Group, Inc. to develop, market, sell, and distribute Prelude SkinPrep system for skin preparation prior to the application of topical anesthetics prior to a range of needle-based medical procedures in North America, the United Kingdom, South America, Australia, New Zealand, Switzerland, and other portions of the European Community; a license agreement with Handok Pharmaceuticals Co., Ltd. to develop, use, market, import, and sell Symphony for continuous glucose monitoring for use by medical facilities and/or individual consumers in South Korea; and a license, development, and commercialization agreement with Medical Technologies Innovation Asia, Ltd. The company was founded in 1989 and is headquartered in Philadelphia, Pennsylvania.

28 Employees
Last Reported Date: 03/28/14
Founded in 1989

echo therapeutics inc (ECTE) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

echo therapeutics inc (ECTE) Key Developments

Echo Therapeutics, Inc. Announces Resignation of Wolf & Company P.C. as Independent Registered Accounting Firm

On December 8, 2014, Echo Therapeutics, Inc. was orally notified by its independent registered accounting firm, Wolf & Company P.C. that it was resigning effective December 8, 2014. The resignation was confirmed in a letter delivered to the company on December 9, 2014.

Echo Therapeutics, Inc. Announces Management Resignations

On November 21, 2014, Charles T. Bernhardt informed Echo Therapeutics, Inc. (Echo) of his decision to resign as Interim Chief Financial Officer and from performing the functions of Principal Executive Officer for Echo effective December 15, 2014. Mr. Bernhardt stated that his resignation was due to his desire to pursue other professional opportunities. Mr. Bernhardt has served in the capacity of Interim Chief Financial Officer since July 16, 2014. On September 12, 2014, Kimberly A. Burke informed Echo of her decision to resign as Senior Vice President, General Counsel and Chief Compliance Officer of Echo to pursue other opportunities. At that time, Ms. Burke agreed to transition matters appropriately and to determine the effective date of her resignation date once an effective transition had occurred. On November 21, 2014, Ms. Burke informed Echo that she had substantially completed the transition of her duties as Echo's Senior Vice President, General Counsel and Chief Compliance Officer and that her resignation would be effective December 5, 2014. Ms. Burke has served as Echo’s General Counsel and Senior Vice President since January 2011, as Chief Compliance Officer since April 2012, and she has served as Echo’s Secretary since 2010. Ms. Burke joined the company as Vice President, Corporate Counsel in 2008.

Echo Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Echo Therapeutics, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, total revenue was $0.02 million against $0.02 million last year. Loss from operations was $2.9 million against $4.9 million last year. Net loss for the third quarter of 2014 was $5.5 million, or $0.43 per basic and diluted share as compared to $5.2 million, or $0.49 per basic and diluted share, for the third quarter of 2013. For the nine months, total revenue was $0.06 million against $0.07 million last year. Loss from operations was $9.5 million against $16.5 million last year. Net loss was $12.0 million, or $0.99 per basic and diluted share as compared to $15.6 million, or $2.06 per basic and diluted share last year.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ECTE:US $1.22 USD +0.03

ECTE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $45.77 USD +1.51
Bayer AG €115.40 EUR +2.08
Johnson & Johnson $106.81 USD +2.74
Roche Holding AG SFr.288.70 CHF +9.70
View Industry Companies
 

Industry Analysis

ECTE

Industry Average

Valuation ECTE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 873.4x
Price/Book 1.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 784.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ECHO THERAPEUTICS INC, please visit www.echotx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.